Literature DB >> 17551395

Nephrogenic rests: their frequency and their fate.

Vito Antonio Caiulo1, Giuseppe Latini, Luigi Cataldi, Claudio De Felice.   

Abstract

Nephrogenic rests (NRs) are considered to be precursor lesions of Wilms tumor, the most common malignant neoplasm of the urinary tract in children. We have previously reported on 2 cases of NRs, incidentally diagnosed at 2 to 3 months of age during an ultrasound mass screening for urinary tract malformations between 1992 and 2006. As the screened population consisted of 17,065 infants, the observed prevalence of NRs in our area in the examined time period was of 1.17/10,000. This is the first reliable estimate of the frequency of clinically appreciable NRs in infants. Microscopic NRs have been found at autopsy in about 1% of infants. Our data are, therefore, helpful in the assessment of the proportion of NRs that disappear spontaneously in the childhood age group. To the best of our knowledge, no false-negative cases were found. Our observations indicate that our policy of "wait and see" is appropriate when NRs are identified incidentally during ultrasonographic screening done for whatever purpose.

Entities:  

Mesh:

Year:  2007        PMID: 17551395     DOI: 10.1097/MPH.0b013e3180601058

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  Ultrasound mass screening for congenital anomalies of the kidney and urinary tract.

Authors:  Vito Antonio Caiulo; Silvana Caiulo; Clara Gargasole; Giovanni Chiriacò; Giuseppe Latini; Luigi Cataldi; Giuseppe Mele
Journal:  Pediatr Nephrol       Date:  2012-01-24       Impact factor: 3.714

Review 2.  Pediatric genitourinary tumors.

Authors:  Sharon M Castellino; Anibal R Martinez-Borges; Thomas W McLean
Journal:  Curr Opin Oncol       Date:  2009-05       Impact factor: 3.645

3.  Extrarenal nephroblastomatosis in children: a report of two cases.

Authors:  Yi Wu; Xueming Zhu; Xingdong Wang; Hangzhou Wang; Xu Cao; Jian Wang
Journal:  BMC Pediatr       Date:  2014-10-06       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.